The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Antiviral treatment for preventing postherpetic neuralgia
Open accessAbstract
BACKGROUND: Postherpetic neuralgia (PHN) is a painful and refractory complication of herpes zoster. Treatments are either partially or totally ineffective for many people with PHN. Antiviral agents, used at the time of the rash, have been proposed as an intervention to prevent the development of PHN. This is the first update since the first publication of the review in 2009. OBJECTIVES: To assess the effectiveness of antiviral agents in preventing PHN. SEARCH METHODS: On 26 April 2013, we updated the searches in the Cochrane Neuromuscular Disease Group Specialized Register, CENTRAL, MEDLINE, EMBASE, LILACS, and the Chinese Biomedical Retrieval System. We checked the references of published studies to identify additional trials, and contacted authors to obtain additional data. We searched other databases in The Cochrane Library for information for the Discussion and two clinical trials registries for ongoing trials. SELECTION CRITERIA: We considered all randomised controlled trials (RCTs) of antiviral treatment given within 72 hours after the onset of herpes zoster for preventing PHN. There were no language restrictions. DATA COLLECTION AND ANALYSIS: Two authors independently selected trials, evaluated the risk of bias in included trials, and extracted and analysed data. MAIN RESULTS: Six RCTs with a total of 1211 participants were eligible; five trials evaluated oral aciclovir, and one, with 419 participants, evaluated oral famciclovir. We were able to conduct meta-analyses as there were sufficient similarities in the included studies, such as the reporting of the presence of PHN, duration of rash before treatment initiation and treatment regimen. For our primary outcome, based on three trials (609 participants) we found no significant difference between the aciclovir and control groups in the incidence of PHN four months after the onset of the acute herpetic rash (risk ratio (RR) 0.75, 95% confidence interval (CI) 0.51 to 1.11), nor was there a significant difference at six months (RR 1.05, 95% CI 0.87 to 1.27, two trials, 476 participants). In four of the trials (692 participants), there was some evidence for a reduction in the incidence of pain four weeks after the onset of rash. In the trial of famciclovir versus placebo, neither 500 mg nor 750 mg doses of famciclovir reduced the incidence of herpetic neuralgia significantly. The most commonly reported adverse events were nausea, vomiting, diarrhoea and headache for aciclovir, and headache and nausea for famciclovir. For neither treatment was the incidence of adverse events significantly different from placebo. None of the studies were at high risk of bias, although the risk of bias was unclear in at least one domain for all but one study. We found no new RCTs when we updated the searches in April 2013. AUTHORS' CONCLUSIONS: There is high quality evidence that oral aciclovir does not reduce the incidence of PHN significantly. In addition, there is insufficient evidence to determine the effect of other antiviral treatments; therefore, further well-designed RCTs are needed to investigate famciclovir or other new antiviral agents in preventing PHN. Future trials should pay more attention to the severity of pain and quality of life of participants, and should be conducted among different subgroups of people, such as people who are immunocompromised.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Topical lidocaine for the treatment of postherpetic neuralgia
Khaliq, W., Alam, S., & Puri, N. K. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004846.pub2 · Cited by 161
RetractedMeasuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
(2008) · Cited by 3,790
Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project
Ware, J. E., & Gandek, B. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00081-x · Cited by 2,605
A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
Oxman, M. N., Levin, M. J., Johnson, G. R., Schmader, K. E., Straus, S. E., Gelb, L. D., Arbeit, R. D., Simberkoff, M. S., Gershon, A. A., Davis, L. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051016 · Cited by 2,412
(2010) · Handbook of Disease Burdens and Quality of Life Measures · doi:10.1007/978-0-387-78665-0_6514 · Cited by 1,385
Published by John Wiley & Sons Ltd
Modarresi, O. A. F., & Shakibaie, M. M. M. R. (2015) · Cited by 1,111
EFNS guidelines on pharmacological treatment of neuropathic pain
Attal, N., Cruccu, G., Haanpää, M., Hansson, P., Jensen, T. S., Nurmikko, T., Sampaio, C., Sindrup, S., & Wiffen, P. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01511.x · Cited by 880
Chapter 12: Interpreting results and drawing conclusions
Schünemann, H. J., Oxman, A. D., Jonathan, J., & Glasziou, P. (2011) · Cited by 870
MacDonald, B. K. (2000) · Brain · doi:10.1093/brain/123.4.665 · Cited by 858
Gnann, J. W., & Whitley, R. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp013211 · Cited by 781
Postherpetic Neuralgia — Pathogenesis, Treatment, and Prevention
Kost, R. G., & Straus, S. E. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607043350107 · Cited by 641
Lefebvre, C., Manheimer, E., & Glanville, J. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch6 · Cited by 559
Epidemiology and Impact on Quality of Life of Postherpetic Neuralgia and Painful Diabetic Neuropathy
Schmader, K. E. (2002) · The Clinical Journal of Pain · doi:10.1097/00002508-200211000-00002 · Cited by 550
Tyring, S., Barbarash, R. A., Nahlik, J. E., Cunningham, A., Marley, J., Heng, M., Jones, T., Rea, T., Boon, R., Saltzman, R., et al. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-2-199507150-00002 · Cited by 491
Wood, M. J., Johnson, R. W., McKendrick, M. W., Taylor, J., Mandal, B. K., & Crooks, J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403313301304 · Cited by 401
Analgesic Therapy in Postherpetic Neuralgia: A Quantitative Systematic Review
Hempenstall, K., Nurmikko, T. J., Johnson, R. W., A'Hern, R. P., & Rice, A. S. C. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020164 · Cited by 400
Whitley, R. J., Weiss, H., Gnann Jr., J. W., Tyring, S., Mertz, G. J., Pappas, P. G., Schleupner, C. J., Hayden, F., Wolf, J., Soong, S.-J., et al. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-5-199609010-00004 · Cited by 386
Field, H. J. (1988) · Cited by 383
Post-herpetic neuralgia: Further post-mortem studies of cases with and without pain
Watson, C. P. N., Deck, J. H., Morshead, C., Van der Kooy, D., & Evans, R. J. (1991) · Pain · doi:10.1016/0304-3959(91)90124-g · Cited by 337
Wood, M. J., Kay, R., Dworkin, R. H., Soong, S. J., & Whitley, R. J. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.2.341 · Cited by 324
Dubinsky, R. M., Kabbani, H., El-Chami, Z., Boutwell, C., & Ali, H. (2004) · Neurology · doi:10.1212/01.wnl.0000140708.62856.72 · Cited by 300
Therapy of herpes zoster with oral acyclovir.
Huff, J. C., Bean, B., Balfour, H. H., Laskin, O. L., Connor, J. D., Corey, L., Bryson, Y. J., & McGuirt, P. V. (1988) · PubMed · Cited by 266
Oral Acyclovir in the Treatment of Acute Herpes Zoster Ophthalmicus
Cobo, L. M., Foulks, G. N., Liesegang, T., Lass, J., Sutphin, J. E., Wilhelmus, K., Jones, D. B., Chapman, S., Segreti, A. C., & King, D. H. (1986) · Ophthalmology · doi:10.1016/s0161-6420(86)33678-9 · Cited by 252
Herpes zoster and postherpetic neuralgia
Loeser, J. D. (1986) · Pain · doi:10.1016/0304-3959(86)90089-8 · Cited by 240
Oral acyclovir in acute herpes zoster.
McKendrick, M. W., McGill, J. I., White, J. E., & Wood, M. J. (1986) · BMJ · doi:10.1136/bmj.293.6561.1529 · Cited by 203
Management of herpes zoster (shingles) and postherpetic neuralgia.
Stankus, S. J., Dlugopolski, M., & Packer, D. (2000) · PubMed · Cited by 186
Efficacy of oral acyclovir treatment of acute herpes zoster.
Wood, M., Ogan, P., McKendrick, M. W., Care, C., McGill, J. I., & Webb, E. (1988) · PubMed · Cited by 182
Jackson, J. L. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.157.8.909 · Cited by 166
Oral acyclovir in the treatment of herpes zoster in general practice.
Morton, P., & Thomson, A. N. (1989) · PubMed · Cited by 164
Corticosteroids for preventing postherpetic neuralgia
Han, Y., Zhang, J., Chen, N., He, L., Zhou, M., & Zhu, C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005582.pub4 · Cited by 140
Self-citationThe Effect of Treating Herpes Zoster With Oral Acyclovir in Preventing Postherpetic Neuralgia
Jackson, J. L. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440290095010 · Cited by 136
Oral acyclovir in herpes zoster ophthalmicus
Harding, S. P., & Porter, S. M. (1991) · Current Eye Research · doi:10.3109/02713689109020376 · Cited by 133
Proposed classification of herpes zoster pain
Dworkin, R., & Portenoy, R. (1994) · The Lancet · doi:10.1016/s0140-6736(94)93106-2 · Cited by 115
Antiviral treatment for preventing postherpetic neuralgia
Li, Q., Chen, N., Yang, J., Zhou, M., Zhou, D., Zhang, Q., & He, L. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006866.pub2 · Cited by 111
Self-citationNatural history of pain following herpes zoster
Thyregod, H. G. H., Rowbotham, M. C., Peters, M., Possehn, J., Berro, M., & Petersen, K. L. (2006) · Pain · doi:10.1016/j.pain.2006.09.021 · Cited by 102
Zoster-associated chronic pain: an overview of clinical trials with acyclovir.
Crooks, R. J., Jones, D. A., & Fiddian, A. P. (1991) · PubMed · Cited by 102
Does treatment of acute herpes zoster prevent or shorten postherpetic neuralgia?
Alper, B. S., & Lewis, P. R. (2000) · PubMed · Cited by 96
Philip, A. G., & Thakur, R. (2011) · Journal of Palliative Medicine · doi:10.1089/jpm.2011.9685 · Cited by 89
Clinical Applications for Change-Point Analysis of Herpes Zoster Pain
Desmond, R. A., Weiss, H. L., Arani, R. B., Soong, S., Wood, M., Fiddian, P. A., Gnann, J. W., & Whitley, R. J. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00393-7 · Cited by 85
[Herpes zoster and post-herpetic neuralgia].
Hashizume, K. (2001) · PubMed · Cited by 82
Lancaster, T., Silagy, C. A., & Gray, S. (1995) · Europe PMC (PubMed Central) · Cited by 81
Persistence of varicalla-zoster virus DNA in elderly patients with postherpetic neuralgia
Mahalingam, R., Wellish, M., Brucklier, J., & Gilden, D. H. (1995) · Journal of NeuroVirology · doi:10.3109/13550289509111018 · Cited by 78
Vafai, A., Wellish, M., & Gilden, D. H. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.8.2767 · Cited by 72
Pathological studies of spinal nerve ganglia in relation to intractable intercostal pain.
Fp, S. (1978) · PubMed · Cited by 47
Vaccination for preventing postherpetic neuralgia
Chen, N., Li, Q., Zhang, Y., Zhou, M., Zhou, D., & He, L. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007795.pub2 · Cited by 35
Self-citationProphylaxis of Herpesvirus Infections in Immunocompetent and Immunocompromised Older Patients
Fillet, A. (2002) · Drugs & Aging · doi:10.2165/00002512-200219050-00003 · Cited by 32
Antiviral treatment for preventing postherpetic neuralgia
Li, Q., He, L., Zhang, Q., Zhou, M., & Zhou, D. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006866 · Cited by 19
Self-citationPost herpetic neuralgia: A review
Griffin, M. J., Chambers, F. A., & MacSullivan, R. (1998) · Irish Journal of Medical Science (1971 -) · doi:10.1007/bf02937940 · Cited by 10
Cited by
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
Cunningham, A. L., Lal, H., Kovac, M., Chlibek, R., Hwang, S.-J., Díez-Domingo, J., Godeaux, O., Levin, M. J., McElhaney, J. E., Puig-Barberà, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603800 · Cited by 1,070
Varicella zoster virus infection
Gershon, A. A., Breuer, J., Cohen, J. I., Cohrs, R. J., Gershon, M. D., Gilden, D., Grose, C., Hambleton, S., Kennedy, P. G. E., Oxman, M. N., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.16 · Cited by 910
Cohen, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmcp1302674 · Cited by 734
The impact of herpes zoster and post-herpetic neuralgia on quality-of-life
Johnson, R. W., Bouhassira, D., Kassianos, G., Leplège, A., Schmader, K. E., & Weinke, T. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-37 · Cited by 404
A systematic review and meta-analysis of risk factors for postherpetic neuralgia
Forbes, H. J., Thomas, S. L., Smeeth, L., Clayton, T., Farmer, R., Bhaskaran, K., & Langan, S. M. (2016) · Pain · doi:10.1097/j.pain.0000000000000307 · Cited by 355
Metadata
- Authors
- Chen, N., Li, Q., Yang, J., Zhou, M., Zhou, D., & He, L.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2014-02-06
- Volume
- 2014
- Issue
- 2
- Pages
- CD006866-CD006866
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1957033039
- Cited by
- 289
- References
- 53
- FWCI
- 18.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.